Table 1.
Characteristics of the patients studied.
| Features | Controls | SS patients | ||||
|---|---|---|---|---|---|---|
| Healthy (n=10) | Sicca (n=11) | NHL (n=6) | SS (n=30) | SSL (n=15) | ||
| General | Age (years), median (range) | 48 (38-72) |
50 (43-78) |
59.5 (34-84) |
60 (27-79) |
70 (53-78) |
| Men/women | 0/10 | 2/9 | 4/2 | 3/27 | 1/14 | |
| Disease Duration (years), median (range) | NA | NA | 0.5 (0.5-8.0) |
10 (0.25-34.0) |
17.0 (4-37.0) |
|
|
Histological
(MSG biopsy) |
Biopsy focus score (number of lymphocytic foci/4mm2), median (range) | NA | 0 (0.0-0.5) |
NA | 2.40 (1.0-10.44) |
3.33 (1.0-10.0) |
| Tarpley biopsy score, median (range) | NA | 0 | NA | 2 (1-3) | 3 (1-3) | |
| Germinal center formation “No,(%)” | NA | 0 (0) | NA | 8 (26.7) | 4 (26.7) | |
| Clinical | Arthralgias “No,(%)” | NA | 1 (9) | NR | 21 (70.0) | 13 (86.7) |
| Arthritis “No,(%)” | NA | 0 (0) | NR | 4 (13.3) | 3 (20.0) | |
| SG enlargement (SGE) “No,(%)” | NA | 0 (0) | NA | 11 (36.7) | 9 (60.0) | |
| Raynaud’s phenomenon “No,(%)” | NA | 0 (0) | NR | 7 (23.3) | 7 (46.7) | |
| Parenchymal organ involvement “No,(%)” | NA | NA | NA | 5 (16.7) | 4 (26.7) | |
| Lung involvement “No,(%)” | NA | NA | NA | 2 (6.7) | 4 (26.7) | |
| Renal involvement “No,(%)” | NA | NA | NA | 0 (0) | 0 (0) | |
| Liver involvement “No,(%)” | NA | NA | NA | 3 (10.0) | 0 (0) | |
| Indicative of vasculitic involvement “No,(%)” | NA | NA | NA | 1 (3.3) | 6 (40.0) | |
| Palpable purpura “No,(%)” | NA | NA | NR | 1 (3.3) | 4 (26.7) | |
| Vasculitis (%)”No,(%)” | NA | NA | NR | 0 (0.0) | 0 (0.0) | |
| Glomerulonephritis “No(%) | NA | NA | NR | 0 (0) | 0 (0) | |
| Peripheral neuropathy “No,(%)” | NA | NA | NR | 1 (3.3) | 2 (13.3) | |
| ESSDAI score, median (range) | NA | NA | NA | 3.5 (0-15) | 19 (12-25) | |
| Laboratory | Anti-Ro/SSA and/or La/SSB positive “No,(%)” | 0 (0) | 0 (0) | NA | 25 (83.3) | 13 (86.7) |
| Anti-Ro/SSA positive “No,(%)” | 0 (0) | 0 (0) | NA | 25 (83.3) | 13 (86.7) | |
| Anti-La(SSB) positive “No,(%)” | 0 (0) | 0 (0) | NA | 13 (43.3) | 8 (53.3) | |
| Rheumatoid Factor positive “No,(%)” | 0(0) | 0 (0) | NA | 15 (50.0) | 13 (86.7) | |
| C3-levels, median (range) | NR | NR | NR | 111.5 (53-160) |
102.0 (86-123) |
|
| C4-levels, median (range) | NR | NR | NR | 20.5 (7.0-45.6) |
14 (1.0-22.4) |
|
| C4- hypocomplementemia “No,(%)” | NR | NR | NR | 7 (23.3) | 10 (66.7) | |
| Cryoglobulinemia “No,(%)” | NA | NA | NR | 0 (0.0) | 5 (33.3) | |
| Hypergammaglobulinemia “No(%)” | NA | NA | NR | 12 (40.0) | 5 (33.3) | |
| Leukopenia “No,(%)” | NA | NA | NR | 1 (3.3) | 1 (6.7) | |
| Treatment | Steroids, “No(%)” | NA | NA | 0 | 2 (6.7) | 0 |
| Hydroxychloroquine, “No(%)” | NA | NA | 0 | 1 (3.3) | 0 | |
| Pilocarpine, “No(%)” | NA | NA | 0 | 2 (6.7) | 0 | |
| Hydroxychloroquine & pilocarpine, “No(%)” | NA | NA | 0 | 2 (6.7) | 0 | |
| Steroids, pilocarpine & hydroxychloroquine, “No(%)” | NA | NA | 0 | 2 (6.7) | 0 | |
| Azathioprine, “No(%)” | NA | NA | 0 | 1 (3.3) | 0 | |
| Hydroxychloroquine & methotrexate, “No(%)” | NA | NA | 0 | 2 (6.7) | 0 | |
| NHL-related treatment administrated prior to sampling | ||||||
| Anti-CD20 (median 4years before sampling; range 2-8), No(%) | NA | NA | 0 | 0 | 7 (46.6) | |
| R-CHOP (DLBCL-pSS patient 7years before sampling), No(%) | NA | NA | 0 | 0 | 1 (6.7) | |
NA, not applicable.
NR, not recorded.
R-CHOP, Rituximab, Cyclophosphamide, Doxorubicin hydrochloride, Vincristine, Prednisolone.